Beyond Five Stars
Follow the six R’s to boost your online presence and counteract negative online reviews.

Reading a negative online review of your practice can feel like a personal attack on you and your staff members. Not only is it hurtful, it is also scary. Practitioners often vacillate between anger and concern about what impact this very public rebuke will have on prospective patients. Their fears are supported by a recent study from Digital Assent showing that, for 72% of patients, negative reviews...

Articles

Beyond Five Stars

Reading a negative online review of your practice can feel like a personal attack on...

Success Through Specialization

Cosmetic dermatologist Tess Mauricio, MD, originally planned to pursue a career in...

Breaking the Barrier

Both fractional lasers and microneedling have been shown to stimulate collagen...

FDA Accepts EVOSYAL New Drug Application

The U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug...

Products

Skin Care: Prime Neck

Valmont Prime Neck is exclusively formulated for the delicate skin on the...

D.E.J. Eye Cream

Revision Skincare’s D.E.J. Eye Cream targets the dermal-epidermal junction...

Professional-C Suncare SPF 30

Obagi Medical’s Professional-C Suncare SPF 30 is a dual-function treatment...

Skin Care: Melt Away Gelee

Melt Away Gelee by Osmosis removes makeup in one swipe of a tissue or cotton...

Cynosure Acquires Ellman International

Cynosure has acquired Ellman International’s assets for approximately $13.2 million cash. Ellman makes the radiofrequency-based Pelleve and Pellefirm skin-tightening systems as well as the Sandstone line of medical aesthetic lasers.
“This transaction complements our brand portfolio, expands our market opportunities and enhances our recurring revenue stream,” said Michael Davin, chairman and CEO of Cynosure. “Ellman's RF product line broadens our technology platform, while its aesthetic lasers allow us to offer a value solution at a different price point than our current offerings.”
Ellman employs about 100 people and Cynosure anticipates retaining all employees as Ellman becomes a division of the company.

FDA Accepts EVOSYAL New Drug Application

The U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for EVOSYAL, a botulinum toxin Type A neurotoxin, from ALPHAEON Corporation, a subsidiary of Strathespy Crown Holdings LLC. The company will now be able to conduct clinical studies to determine the safety and efficacy of EVOSYAL in pursuit of FDA aproval.
“EVOSYAL represents the state-of-the-art in both consistent manufacturability and potency as a 900 kDa neurotoxin molecular complex with high purity, both of which we believe will aid in achieving precise, predictable and long-lasting patient outcomes,” said John Gross, MD, chief scientific officer for Evolus, a division of ALPHAEON.
The initial clinical trial is anticipated to be fully enrolled by the end of 2014.

Image copyright iStock

Registration Now Open for ASDS Annual Meeting

The 2014 American Society for Dermatologic Surgery (ASDS) Annual Meeting will take place on November 6-9 in San Diego, California. The educational event will consist of more than 65 scientific sessions and allow attendees to network, learn about significant research and techniques, participate in hands-on courses, and explore new technologies to stay on the cutting edge of dermatologic surgery.
For more information, visit asds.net.